CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Compass posts positive psilocybin data; Solstice makes $225M debut

Data ReadoutpositiveCOMP360Positive
AI Analysis

Summary

Compass Pathways reported positive one-year data for its psilocybin drug COMP360, while Solstice completed a $225M debut offering.

Clinical Trial Data

Outcome Details

One-year data for psilocybin drug COMP360

Importance:6/10
Sentiment:
0.70
psilocybinclinical trial dataIPOmental health
Related Companies

Read the original article

Published by Endpoints News on September 9, 2026 3:35 PM

Read Original